Technology
HDT Bio and UTMB partner against CCHFV and NiV
In November 2022 HDT Bio Corp. and the University of Texas Medical Branch (UTMB) revealed that they had been awarded a project agreement worth up to $87.4 m
PharmaJet announces grant from NIH for HPV
PharmaJet announced that it had received an NIH grant towards their Phase II investigation of the immunogenicity of intradermal administration of HPV vaccine.
CEPI collaboration with UQ on Disease X platform
In November 2022 CEPI announced an investment of U$5.7 million towards the development of a second-generation molecular clamp vaccine platform at the UQ
Exclusive interview with Dr Ariel Weinberger
With the World Vaccine and Immunotherapy Congress just days away we are delighted to share another exclusive interview with the community
Exclusive interview with Dr Erin Spiegel
While we were in Barcelona this year for the World Vaccine Congress 2022 we had the exciting opportunity to meet Dr Erin Spiegel.
A very modern challenge: The Human Immunome Project
“Pioneering a new era of human health”, scientists at the Human Immune Project are tackling “one of the greatest remaining frontiers”: the human immune system. Formerly known as the Human Vaccines Project, and modelled after the Human Genome Project, they are...
GSK Shingrix vaccine success drives ¾ revenues
A November press release from GSK indicates a rise in revenue and profit, attributed to its Shingrix vaccine for shingles. Pharmaphorum suggests that, since the “spin-off” from Haleon in July it has “exceeded analysts’ estimates”. Positive quarter GSK recorded an...
Vaxxinity platform aims to conquer chronic diseases
Migraines affect an estimated 10% of people worldwide, causing severe headaches and other symptoms such as light sensitivity, nausea, and vomiting. The WHO reports that migraines are “more common in women, usually by a factor of about 2:1”. This is attributed to...
Sanofi deploys Dassault’s virtual twin experiences
In October 2022 Sanofi and Dassault Systemes announced a partnership to optimise Sanofi’s “EVolutive Facilities” (EVF). These are “state-of-the-art" manufacturing sites powered by “big data and digital”, and Sanofi describes them as the “future of vaccine...
On Polio Day PharmaJet announces USAID grant
The 24th of October 2022 was World Polio Day, which draws attention to the continued global fight against polio. This year, PharmaJet, the developer of a needle-free delivery platform, announced that it had received a multi-year grant from the United States Agency for...
WHO and IDIA renew agreement for health impact
In October 2022 the WHO announced the renewal of a strategic Collaboration Agreement with the International Innovation Alliance (IDIA) to “support the scaling of health innovations to the end of 2023”. The WHO outlined a shared goal: “to jointly accelerate health...
Airfinity predicts jab price increase to meet demand
In October 2022 the health analytics specialist Airfinity predicted that the COVID-19 vaccine market will generate $60 billion for this year, despite a drop in sales. Airfinity suggests that this will come at a cost for buyers, who will face an increase in price per...
GSK announces positive results for RSV candidate
In a press release on 13th October 2022 GSK plc announced “positive pivotal phase III trial results” for a vaccine candidate against respiratory syncytial virus (RSV). The vaccine is for adults of 60 years and older and is in direct competition with Pfizer’s RENOIR...
Japan’s 100-day ambitions funded in SCARDA
In September 2022 Japan’s Strategic Centre of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) announced its investment in future vaccine research. An article in Nature suggested that this comes after Japan recognised it was...
CEPI announces funding for intranasal vaccines
In October 2022 CEPI and the Dutch vaccine developer Intravacc announced funding to for broad protection against variants of COVID-19 and other Betacoronaviruses. This is part of CEPI’s $200 million programme for broad protection vaccines. CEPI announced that it...
South African vaccine attempt slammed by pharma giants
During the COVID-19 pandemic the stark inequalities of our world were highlighted by disparities in vaccine development, production, and distribution. Despite the WHO goal of 70% coverage across the world by mid 2022, the reality was very different. Thus, a plan to...
Moderna denies China access to vaccine technology
In October 2022 the Financial Times reported that Moderna had refused China’s request for the intellectual property behind its revolutionary COVID-19 vaccine. This resulted in a “collapse in negotiations” for its sale in the country. Although Moderna is still hoping...
Australian collaborators awarded contract for TB vaccines
The Centenary Institute in Sydney and the University of Sydney announced in September that they, alongside collaborators, had been awarded a contract from the US NIAID. The contract, worth AU$19 million, will fund the development of the next generation of tuberculosis...
Zika vaccine technology shows mouse model promise
Results published in Microbiology Spectrum by researchers from the US demonstrate that their Zika vaccine technology is safe and effective in preclinical mouse models. As it stands there are no approved vaccines or alternative treatments for virus, but these results...
Vaxxas to receive further funding for patch technology
Vaxxas announced in September 2022 that it will receive an AU$8.2 million grant from the Australian Federal Government as part of the Modern Manufacturing Initiative (MMI). This will promote the scale-up of its “potentially game-changing technology” that enables...
